Biosimilars

The partial government shutdown is affecting the country in many ways-but how is it interfering with biosimilar development?

With a new ruling against the Affordable Care Act (ACA), many worry about the fate of the biosimilar market. But will it be as detrimental as feared?

2018 was meant to be a big year for the biosimilar market-but were developments as big as hoped? Find out.

In an effort to lower prescription drug prices, CMS unveiled proposed polices for 2020 to strengthen and modernize the Medicare Part C and D programs. Here’s a closer look at what CMS’ provisions entail and how they help accomplish the Administration’s four strategies.

With all eyes on drug prices, payers are looking to biosimilar agents to cut costs-and improve patient outcomes.

The biosimilar market is flourishing in Europe-why aren’t we seeing similar gains in the U.S.?

Despite a scolding from President Trump over drug price hikes, drug giant Pfizer announced it will raise the prices of 41 medications in January. That’s 10% of its entire drug portfolio.

Here are five things managed care executives should know about the proposed plan.

The value and benefits of biosimilars are increasingly becoming more apparent. Here are four areas where they are growing the most.

This comprehensive, pay-for-performance approach drives clinical quality and affordability.

Biosimilar agents can help healthcare organizations offer patients more options for their care. So, what’s stopping payers from immediately adding them to their formularies?

As healthcare organizations move toward value-based models of reimbursement, high drug prices can sometimes get in the way of optimal care. Here are three ways that biosimilars may help.

A new report from IQVIA reveals interesting findings on orphan drug spending and the impact of orphan drug biosimilars on patient costs.

Biosimilars hold great cost savings promises for payers and patients alike-but only if prescribers and patients are willing to make the switch.

Better care at lower costs is the ultimate goal across healthcare today. Here’s how pharmacists can help.

The hope is that more biosimilars will lead to more access and more affordable medications, but biosimilar uptake is lagging. Here’s why and how FDA hopes to fix it.

Prices of more than 20% of generic drugs increased more than 100% between 2010 and 2015.

Healthcare experts weigh in on the president’s plan to lower drug prices. Here’s what they said.

The new Bipartisan Budget Act of 2018 (to be in effect on January 2019) institute new reimbursement guidelines for biosimilars under the Medicare coverage gap discount program that remove disincentives for biosimilar uptake and level the playing field for the future market place.

Understanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.

The impact of VBRs on outcomes, VBRs versus other healthcare reimbursement initiatives, and VBR successes and failures. Pfizer’s Robert Popovian, PharmD, weighs in.

How are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.

The next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.

Biosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.

Awareness of biosimilars is high, but there are some gaps to be filled, according to a Biosimilars Forum study.

Biosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting?